SCYX SCYNEXIS Inc.

0.76
-0.02  -3%
Previous Close 0.78
Open 0.8
Price To Book 5.84
Market Cap 74,027,349
Shares 97,417,224
Volume 412,080
Short Ratio
Av. Daily Volume 733,561
Stock charts supplied by TradingView

NewsSee all news

  1. SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

    JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,

  2. SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

    Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as

  3. SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

    Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipientsSCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus infections: FURI

  4. SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

    JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it

  5. SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

    JERSEY CITY, N.J., Jan. 8, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data presented at ECCMID April 13, 2019.
SCY-078 - oral - CARES
Candida Auris
Phase 2 trial initiated 3Q 2018. Enrolment continues to enrol as of March 11, 2020.
Ibrexafungerp (SCY-078) - SCYNERGIA
Invasive aspergillosis
Phase 3 data met primary endpoint - November 7, 2019.
SCY-078 - oral ibrexafungerp - VANISH 303
Vulvovaginal candidiasis (VVC)
Phase 3 second interim analysis January 8, 2020. Overall response rate 56%.
SCY-078 - oral (FURI)
Invasive candidiasis
Phase 3 data and sNDA filing due 2H 2021.
SCY-078 - ibrexafungerp - CANDLE
Recuurent Vulvovaginal candidiasis (VVC)
Phase 3 data due early 2Q 2020.
SCY-078 - oral ibrexafungerp - VANISH 306
Vulvovaginal candidiasis (VVC)

Latest News

  1. SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

    JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,

  2. SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

    Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as

  3. SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

    Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipientsSCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus infections: FURI

  4. SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

    JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it

  5. SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

    JERSEY CITY, N.J., Jan. 8, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive

  6. SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors

    JERSEY CITY, N.J., Dec. 16, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the

  7. SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants

    JERSEY CITY, N.J., Dec. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc.

  8. SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants

    JERSEY CITY, N.J., Dec. 10, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX) today announced the pricing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to

  9. SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

    JERSEY CITY, N.J., Dec. 9, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants.

  10. SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States

    JERSEY CITY, N.J., Nov. 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc.

  11. SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update

    JERSEY CITY, N.J., Nov. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported

  12. SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

    JERSEY CITY, N.J., Nov. 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive

  13. SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress

    JERSEY CITY, N.J., Oct. 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that

  14. SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

    JERSEY CITY, N.J., Oct. 24, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced an

  15. SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program

    JERSEY CITY, N.J., Oct. 10, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, has received

  16. SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris

    JERSEY CITY, N.J., Oct. 2, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that

  17. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  18. SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

    JERSEY CITY, N.J., Sept. 18, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced

  19. SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences

    JERSEY CITY, N.J., Sept. 4, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that